Singularity Biomed Secures ENISA Funding to Accelerate Technology Development

We are thrilled to announce that Singularity Biomed has been granted a participatory loan from ENISA (Empresa Nacional de Innovación, S.A.). This funding represents a significant vote of confidence in our vision and the technological potential of our solutions for Rheumatoid Arthritis (RA).

What is ENISA?

ENISA is a state-owned company attached to the Spanish Ministry of Industry, Trade and Tourism. Its mission is to actively participate in the financing of viable and innovative business projects proposed by Spanish SMEs and entrepreneurs.

Receiving support from ENISA is not just about financial backing; it serves as a seal of quality and innovation, recognizing the viability and potential impact of our business model and technology.

Accelerating Innovation in Healthcare

This funding comes at a crucial moment for Singularity Biomed. It will allow us to:

1. Advance R&D: Continue the development of our machine learning model for analyzing thermal images.
2. Enhance Scientific Evidence: Support ongoing and future clinical studies.
3. Scale Operations: Strengthen our team to prepare for upcoming regulatory and market challenges.

At Singularity Biomed, we are committed to transforming the management of autoimmune diseases through Artificial Intelligence. The support from ENISA provides the resources needed to push our boundaries further and bring our solution closer to the patients and clinicians who need it.

We are grateful for this recognition and excited about the path ahead.